MCKESSON CORP

Company Overview

McKesson is a large, diversified healthcare services and distribution company operating four reportable segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical‑Surgical Solutions (planned for separation), and International (primarily Canada). Its core operations combine high‑volume pharmaceutical and medical‑surgical distribution with technology and logistics services (electronic prior authorization, price transparency, large pharmacy/provider connectivity), producing FY2025 revenues of $359.1 billion and diluted EPS of $25.72. The business is scale‑dependent and automation‑driven, with heavy customer concentration (top 10 customers ≈72% of revenue; CVS ≈24%), significant supplier concentration, and material regulatory exposures (DEA/FDA/DSCSA, HIPAA/PIPEDA, antitrust and drug‑pricing laws). Recent themes include share repurchases and dividends, active M&A (Core Ventures, PRISM Vision), ongoing restructuring to modernize tech, and material litigation/program liabilities (notably ~$6.4 billion in opioid‑related liabilities).

Executive Compensation Practices

Given McKesson’s scale and business model, executive pay is likely tied to a mix of financial, operational, and strategic metrics: adjusted EPS or adjusted operating income, free cash flow/operating cash flow, gross margin and working capital efficiency (inventory/LIFO effects), and segment/strategic milestones (RxTS volume/connectivity metrics, successful Medical‑Surgical separation, and M&A integration). Long‑term incentives are typically equity‑based (RSUs, performance share units, options) and will often include TSR and multi‑year adjusted EPS or ROIC targets; management may negotiate retention or special awards tied to the planned separation and recent acquisitions. Compensation committees will frequently rely on adjusted (non‑GAAP) performance measures to exclude one‑time items (LIFO charges, settlement receipts, restructuring)—meaning payouts can be sensitive to accounting adjustments. Pay design will also reflect regulatory and litigation risk (clawback provisions, change‑in‑control protections, and compliance scorecards) and the company’s opportunistic capital return policy (repurchases/dividends) which affects share count and equity‑based award dilution and vesting values.

Insider Trading Considerations

Insider trading at McKesson can be influenced by frequent, material operational events: national account contract renewals or volume changes (CVS concentration), material litigation developments (opioid settlements, Rite Aid exposures), antitrust or regulatory rulings, and discrete M&A or separation milestones for Medical‑Surgical. Executives will face standard Section 16 reporting, company blackout windows around earnings, and likely internal policies limiting trades when material nonpublic information exists; many insiders use pre‑planned Rule 10b5‑1 plans to manage predictable liquidity events such as RSU vesting or option exercises. Watch for clustered Form 4 activity following dividend/repurchase announcements or after the board sets separation/transaction milestones—timing of sales relative to non‑GAAP adjustments (e.g., restructuring exclusions, settlement receipts) can attract investor scrutiny and SEC attention. Finally, because regulatory compliance (DSCSA traceability, HIPAA, antitrust) can produce sudden material disclosures, even operations‑level updates can move the stock and create heightened insider‑trading risk.